About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

The Company’s second therapeutic platform, the CardiALLO™  Cell Therapy System, is an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of cardiac and pulmonary disease.



News

15 Sep

BioTuesdays

BioCardia developing autologous and allogenic cardiovascular cell therapies
Read More
03 Aug

Pharmaceutical Technology

BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
Read More
28 Jul

The Big Biz show

The Big Biz Show interviews BioCardia CEO, Peter Altman
Read More
10 Jan

HealthCare Weekly

5 Innovations That Will Change the Treatment of Heart Disease
Read More
28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More

press releases

11 Jan
2021 Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors
30 Dec
2020 BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
17 Dec
2020 BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
16 Dec
2020 BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The Market Under NASDAQ Rules
14 Dec
2020 BioCardia Anticipates DSMB Feedback on Interim Data from Pivotal Phase 3 CardiAMP Heart Failure Trial
14 Dec
2020 BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS